Haupt Pharma has completed its merger with fellow German companies Amareg and Wülfing Pharma to create a major new force in the European contract development and manufacturing sector, with around 1,500 staff and an annual turnover of €180m.
All three companies are owned by Invita AG, an investment company that focuses on the pharmaceutical sector, which said at the time the deal was first announced in June that the merger would create a company with “a broad range of manufacturing technologies which will ... complement one another.”
The consolidated company trades under the internationally established brand name of Haupt Pharma, with Gronau-based of Wülfing Pharma renamed Haupt Pharma Wülfing, and Regensburg company Amareg now known as Haupt Pharma Amareg.
After the merger, the group will have eight manufacturing sites, making it one of the largest contract manufacturing organisations (CMOs) in Europe, working with 15 of the top 25 pharmaceutical companies and producing more than 1,500 different lines in 4,000 stock-keeping units, spanning solid, semi-solid, liquid, sterile and specialty products such as hormones, narcotics, cytotoxics and enzymes.
As a result of a “better market setup,” Haupt Pharma said it will be able to generate further growth, strengthen its individual locations for the future and secure jobs over the long term.
The merger will also bring benefits in terms of scale at a time when pharmaceutical customers are “interested in limiting the number of their service providers and awarding all-inclusive contracts in order to restrict the complexity of the cooperations in which they are involved,” said the firm.
Haupt Pharma will also be able to expand its range of services in galenic and analytical development, the production of clinical samples and marketing authorisations.
"Through the consolidation with AMAREG and Wülfing Pharma, we are now ideally placed to carry out the first step of further expanding our European business and then improve our market position in the US and Japan," said Hans-Christian Semmler, chairman of Haupt Pharma.
Amareg focuses mainly on the contract manufacturing of cytostatics in the form of film-coated tablets and capsules, as well as liquid and semisolid forms of conventional drugs. It has 175 employees and generated a turnover of €22m last year. Wülfing employs 300 workers and with a 2007 turnover of €33m, and focuses on a broad range of solid and parenteral lines.
They have been rolled into Haupt Pharma group that has a staff of 900 and sales of €113m last year.